Pralmorelin (GHRP-2)

Fat LossGHRP-2 / diagnostic GH secretagogueExperimental

Also known as: KP-102, GPA 748

Pralmorelin (GHRP-2), also called KP-102 or GPA 748, is a diagnostic GH secretagogue in the Growth Hormone Secretagogue class. Pralmorelin, also called GHRP-2, is a synthetic agonist at growth hormone secretagogue receptor 1a that produces potent growth hormone release through combined direct pituitary stimulation and reduced hypothalamic somatostatin tone.

Calculate Dose

For research use only.

Key Facts

CAS
158861-67-7
Molecular Weight (MW)
801.98 g/mol
Half-life
Reported short; human diagnostic use in Japan
FDA status
Not Approved
FDA compounding lists
503A Category 3, 503B Category 2
Evidence level
Limited Human Evidence
Human dose established
Yes
Administration Route
Intravenous
Frequency
Single bolus as a stimulation test
Last updated
Sep 6, 2026
Reviewed
Sep 5, 2026
Targets
GHSR

Vendor price snapshot

Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.

Vendors listing this peptide
13
Listed offers
21
Median price per mg
$4.25/mg
Typical $3.70–$7.06/mg

Open calculator · Compare vendors

Research summary

Pralmorelin is GHRP-2, used as a GH-stimulation diagnostic in Japan. Research vials are not that approved diagnostic. WADA S2 names GHRP-2 (pralmorelin).

Research evidence

  • Regulatory review (FDA label)None in reviewed sources
  • Controlled human trialsNone in reviewed sources
  • Early or uncontrolled human studies2 reviewed sources
  • Lab & animal studiesNone in reviewed sources
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Pralmorelin (GHRP-2) profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Pralmorelin (GHRP-2) dosage evidence

GHRP-2, developed as pralmorelin, has established human dosing for one narrow purpose: a 100 mcg intravenous bolus used as a growth hormone stimulation test. It is a recognised diagnostic alternative to the insulin tolerance test in Japan. There is no FDA-labelled product and no trial establishing a repeated-dosing regimen for growth hormone or body-composition use.

Limited Human Evidence
Dosage evidence summary for Pralmorelin (GHRP-2)
Human dosing establishedYes
Studied dose range100 mcg intravenous bolus (diagnostic test dose)
RouteIntravenous
FrequencySingle bolus as a stimulation test
Duration studiedAcute; sampling over 60 minutes
Evidence levelLimited Human Evidence
Last reviewed2026-09-05

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Pralmorelin (GHRP-2), one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
Vasopressin secretion study in healthy men (2010)Clinical trial · Human endocrine physiology study10 healthy men, fasting and non-fasting100 mcgIntravenous bolusSingle doseSampling at 15, 30, 45 and 60 minutesACTH, GH, FSH, LH, prolactin, TSH and vasopressin responsesGH-releasing peptide-2 does not stimulate arginine vasopressin secretion in healthy men. Endocr J. 2010.
Diagnostic comparison against the insulin tolerance test (2013)Clinical trial · Diagnostic accuracy study71 pre-operative adults with pituitary tumours, aged 18-65Per the standard GHRP-2 test protocolIntravenousSingle stimulation testAcuteDiagnosis of adult growth hormone deficiency versus the insulin tolerance testThe arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients. Endocr J. 2013.
Development profile - pralmorelinResearch-reported · Drug development profileDevelopment-stage summaryNo maintenance regimen reportedVarious——Development status of GHRP-2 / KP-102Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN. Drugs R D. 2004.

Where sources disagree

  • The 100 mcg dose is a single diagnostic stimulus given once in a clinic to provoke a measurable growth hormone response. It is not a treatment dose, and nothing about it validates repeated administration. GHRP-2 is nonetheless sold with protocols of 100-300 mcg two or three times daily.
  • GHRP-2 raises ACTH, cortisol and prolactin as well as growth hormone. That is documented in the same human studies used to support its growth hormone effect.
  • Approval as a diagnostic agent in Japan does not create a US approved dose, and DailyMed lists no product under pralmorelin or GHRP-2.

Reconstitution

Common research vial sizes: 5 mg, 10 mg.

Reconstitution arithmetic for Pralmorelin (GHRP-2)
VialBacteriostatic waterConcentrationPer 0.01 mL
5 mg2 mL2.5 mg/mL25 mcg per 0.01 mL
10 mg2 mL5 mg/mL50 mcg per 0.01 mL

These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.

Calculate reconstitution & dose →
Pralmorelin (GHRP-2) dosage in published studies and labels →

Handling & administration

Injection Sites
Per protocol
Timing Notes
Ghrelin receptor (GHSR) agonist

Sequence & molecular data

Sequence and molecular data for Pralmorelin (GHRP-2)
Molecular formulaC45H55N9O6
Molecular weight801.98 g/mol
CAS number158861-67-7
Half-lifeReported short; human diagnostic use in Japan
AppearanceWhite lyophilized powder (acetate)
FormulationLyophilized Powder
PubChem CID6918245
FDA UNIIE6S6E1F19M
ChEMBLCHEMBL106593

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Pralmorelin, also called GHRP-2, is a synthetic agonist at growth hormone secretagogue receptor 1a that produces potent growth hormone release through combined direct pituitary stimulation and reduced hypothalamic somatostatin tone. It is more potent than GHRP-6 at releasing growth hormone but retains meaningful activity on the corticotroph axis, commonly raising ACTH and cortisol, and it stimulates appetite. It has an approved diagnostic use in Japan as an intravenous test of growth hormone secretory reserve; that single-dose diagnostic context is pharmacologically distinct from the repeated subcutaneous research use for which it is sold elsewhere.

Origin

Synthetic hexapeptide GHRP.

Targets

GHSR

Research statistics

202 PubMed publications · 45.0% human clinical research · 0 registered trials

Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Pralmorelin (GHRP-2) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Pralmorelin (GHRP-2)
FDA statusNot Approved
AvailabilityResearch-Only
WADA (sport)Banned in Sport
Library classificationResearch-Only

FDA compounding status

These FDA lists track substances nominated for use in pharmacy compounding. Being on a list is not FDA approval and doesn't mean a product is safe or effective.

FDA compounding lists that name Pralmorelin (GHRP-2)
503A Category 3Nominated without adequate support FDA source
503B Category 2FDA identified significant safety risks (injectable and nasal routes) FDA source

FDA list dated May 14, 2026.

How FDA approval, compounding and research-only status differ

Benefits

GH-axis diagnostic literatureSecretagogue research

Pralmorelin (GHRP-2) side effects

Pralmorelin (GHRP-2) has only limited human data, so the list below is incomplete and its side-effect profile is not well established.

Side Effects

  • Hunger
  • Cortisol rise
  • Flushing

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Read the full guide: how to store peptides before and after reconstitution →

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

Pralmorelin (GHRP-2): frequently asked questions

What is Pralmorelin (GHRP-2)?

Pralmorelin is GHRP-2, used as a GH-stimulation diagnostic in Japan. Research vials are not that approved diagnostic. WADA S2 names GHRP-2 (pralmorelin).

How does Pralmorelin (GHRP-2) work?

Pralmorelin, also called GHRP-2, is a synthetic agonist at growth hormone secretagogue receptor 1a that produces potent growth hormone release through combined direct pituitary stimulation and reduced hypothalamic somatostatin tone. It is more potent than GHRP-6 at releasing growth hormone but retains meaningful activity on the corticotroph axis, commonly raising ACTH and cortisol, and it stimulates appetite.

Is Pralmorelin (GHRP-2) FDA approved?

No. Pralmorelin (GHRP-2) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A Category 3: Nominated without adequate support; 503B Category 2: FDA identified significant safety risks (injectable and nasal routes).

What is the half-life of Pralmorelin (GHRP-2)?

Reported half-life for Pralmorelin (GHRP-2) is Reported short; human diagnostic use in Japan. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

Is Pralmorelin (GHRP-2) banned in sport?

Pralmorelin (GHRP-2) is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

What peptides are similar to Pralmorelin (GHRP-2)?

Compounds most often compared with Pralmorelin (GHRP-2) include Ipamorelin, GHRP-6, GHRP-1 and Hexarelin (Examorelin). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 6, 2026 · Version 2

This Pralmorelin (GHRP-2) profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Pralmorelin (GHRP-2) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →